Signs, mimicking chronic glomerulonephritis activity


Cite item

Full Text

Abstract

Some clinical and laboratory features - haematuria, arterial hypertension and worsening of renal function can sometimes mimic the activity of chronic glomerulonephritis. Wrong interpretation of the signs and symptoms can lead to false clinical decisions. Innovative approaches to chronic glomerulonephritis activity monitoring include evaluation of urinary excretion of inflammatory and fibrogenic mediators, as well as immune cells and podocytes

About the authors

N A Moukhin

References

  1. Мухин Н.А. Существует ли гломерулонефрит? // Архив патологий. 1987. № 49(1). С. 76-79.
  2. Тареева И.Е. Механизмы прогрессирования гломерулонефрита // Терапевтический архив. 1996. № 6. С. 5-10.
  3. Alexopoulos E., Gionanlis L., Papayianni E. et al. Predictors of outcome in idiopathic rapidly progressive glomerulonephritis (IRPGN). B.M.C. Nephrol. 2006;7:16.
  4. Orth S.R., Ritz E. The nephritic syndrome. N. Engl. J. Med. 1998;338:1202-11.
  5. Barratt J., Feehally J. IgA nephropathy. J. Am. Soc. Nephrol. 2005;16(7): 2088-97.
  6. Шилов Е.М., Фомин В.В. Гематурия. В: Шилов Е.М. (ред.). Нефрология. М., ГЭОТАР-Медиа. 2008. С. 141-147.
  7. Stillwell T.J., Benson R.C. Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer. 1988;61(3):451-57.
  8. Fraiser L.H., Kanekal S., Kehrer J.P. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991;42(5):781-95.
  9. Kimura M., Tomita Y., Morishita H., et al. Presence of mucosal change in the urinary bladder in nonhematuric patients with long-term exposure and/or accumulating high-dose cyclophosphamide. Possible significance of follow-up cystoscopy on preventing development of cyclophosphamide-induced hemorrhagic cystitis. Urol. Int. 1998;61(1):8-11.
  10. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann. Intern. Med. 1996;124(5):477-84.
  11. Matsuoka Y., Masuda H., Yokoyama M., et al. Protective effects of heme oxygenase-1 against cyclophosphamide-induced haemorrhagic cystitis in rats. B.J.U. Int. 2007;100(6):1402-08.
  12. Büyüknacar H.S., Kumcu E.K., Goçmen C., et al. Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats. Eur. J. Pharmacol. 2008;586(1-3):293-99.
  13. Тареева И.Е., Андросова С.О. Влияние ненаркотических анальгетиков и нестероидных противовоспалительных препаратов на почки // Терапевтический архив. 1999. № 6. С. 17-21.
  14. Pommer W., Glaeske G., Molzahn M. The analgesic problem in the Federal Republic of Germany: analgesic consumption, frequency of analgesic nephropathy and regional differences. Clin Nephrol. 1986;26:273-78.
  15. Cosyns J.P. Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. Drug Saf. 2003;26:33-48.
  16. Krause I., Cleper R., Eisenstein B., et al. Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children. Pediatr. Nephrol. 2005;20(9):1295-98.
  17. Haas M., Spargo B.H., Wit E.J., et al. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am. J. Kidney Dis. 2000;35(3):433-47.
  18. Hurlen M., Eikvar L., Seljeflot I., Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II subgroup analysis. Thromb. Res. 2006;118(4):433-38.
  19. Davydov L., Yermolnik M., Cuni L.J. Warfarin and amoxicillin/clavulanate drug interaction. Ann. Pharmacother. 2003;37(3):367-70.
  20. Cheung B., Lam F.M., Kumana C.R. Insidiously evolving, occult drug interaction involving warfarin and amiodarone. B.M.J. 1996;312(7023):107-08.
  21. Day R., Quinn D. Adverse interaction between warfarin and indomethacin. Drug Saf. 1994;11(3):213-14.
  22. Copur M.S., Ledakis P., Bolton M., et al. An adverse interaction between warfarin and capecitabine: a case report and review of the literature. Clin. Colorectal. Cancer. 2001;1(3):182-84.
  23. Keeler B., Ghani K.R., Nargund V. Haematuria 1: risk factors, clinical evaluation and laboratory investigations. Br. J. Hosp. Med. (Lond.). 2007;68(8):418-22.
  24. Bryden A.A., Paul A.B., Kyriakides C. Investigation of haematuria. Br. J. Hosp. Med. 1995;54(9):455-58.
  25. Boman H., Hedelin H., Holmang S., et al. The results of routine evaluation of adult patients with haematuria analysed according to referral form information with 2-year follow-up. Scand. J. Urol. Nephrol. 2001;35(6):497-501.
  26. Sultana S.R., Goodman C.M., Byrne D.J., et al. Microscopic haematuria: urological investigation using a standard protocol. Br. J. Urol. 1996;78(5):691-96.
  27. Мухин Н.А., Хасабов Н.Н. Паранеопластические нефропатии. В кн.: Тареева И.Е. (ред.) Нефрология. М., 2000. С. 540-545.
  28. Park S.B., Cho K.S., Lee J.H., et al. Unusual manifestations of renal cell carcinoma. Acta Radiol. 2008;49(7):839-47.
  29. Kelly J.D., Fawcett D.P., Goldberg L.C. Assessment and management of non-visible haematuria in primary care. B.M.J. 2009;338:a3021.
  30. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr. Probl. Cancer. 2001;25(4):219-78.
  31. Ghani K.R., Keeler B., Nargund V. Haematuria 2: Imaging investigations, management and follow up. Br. J. Hosp. Med. (Lond). 2007;68(9):489-93.
  32. Murare H.M., Taylor P. Haematuria and proteinuria during Schistosoma haematobium infection: relationship to intensity of infection and the value of chemical reagent strips for pre- and post-treatment diagnosis. Trans. R. Soc. Trop. Med. Hyg. 1987;81(3):426-30.
  33. Hosseini S.R., Mohseni M.G., Atharikia D. Role of sexual intercourse in hematuria and proteinuria in males and females. Urol. Int. 2008;81(3):271-74.
  34. Asghar M., Ahmed K., Shah SS. Renal vein thrombosis. Eur. J. Vasc. Endovasc. Surg. 2007;34(2):217-23.
  35. Robinson S., Nichols D., Macleod A., et al. Acute renal artery embolism: a case report and brief literature review. Ann. Vasc. Surg. 2008;22(1):145-47.
  36. Шилов Е.М., Козловская Н.Л., Метелева Н.А. и др. Клинические проявления нефропатии, связанной с антифосфолипидным синдромом, при первичном антифосфолипидном синдроме // Терапевтический архив. 2003. № 6. С. 22-27.
  37. Nzerue C.M., Hewan-Lowe K, Pierangeli S., et al. "Black swan in the kidney": renal involvement in the antophospholipid antibody syndrome. Kidney Int. 2002;62:733-44.
  38. Таранова М.В., Белокриницкая О.А., Козловская Л.В. и др. "Маски" подострого инфекционного эндокардита // Терапевтический архив. 1999. № 1. С. 47-50.
  39. Bernhardt P., Schmidt H., Hammerstingl C., et al. Atrial thrombi - a prospective follow-up study over 3 years with transesophageal echocardiography and cranial magnetic resonance imaging. Echocardiography. 2006;23(5):388-94.
  40. Korzets Z., Plotkin E., Bernheim J., et al. The clinical spectrum of acute renal infarction. Isr. Med. Assoc. J. 2002;4(10):781-84.
  41. Hazanov N., Somin M., Attali M., et al. Acute renal embolism. Forty-four cases of renal infarction in patients with atrial fibrillation. Medicine (Baltimore). 2004;83(5):292-99.
  42. Кутырина И.М., Мартынов С.А., Швецов М.Ю. и др. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения // Терапевтический архив. 2004. № 9. С. 10-15.
  43. Ridao N., Luno J., Garsia de Vinuesa S., et al. Prevalence of hypertesion in renal disease. Nephrol. Dial. Transplant. 2001;16(Suppl. 1):70-73.
  44. Мухин Н.А., Фомин С.В., Моисеев С.В. и др. Нефрогенная артериальная гипертония: эволюция лечения // Терапевтический архив. 2005. № 8. С. 70-78.
  45. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-08.
  46. Комитет экспертов РМОАГ/ВНОК. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). М., 2008.
  47. Brown M.A., Buddle M.L., Martin A. Is resistant hypertension really resistant? Am. J. Hypertens. 2001;14(12):1263-69.
  48. Mezzetti A., Pierdomenico S.D., Costantini F., et al. White-coat resistant hypertension. Am. J. Hypertens. 1997;10(11):1302-07.
  49. Wetzels G.E., Nelemans P., Schouten J.S., et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J. Hypertens. 2004;22:1849-55.
  50. Patel BV, Remigio-Baker RA, Mehta D., et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J. Clin. Hypertens. (Greenwich). 2007;9(9):692-700.
  51. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии // Сердце. 2005. Т. 4. № 3. С. 120-126.
  52. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Сurr. Med. Chem. Cardiovasc. Hematol. Agents. 2004;2:197-208.
  53. Чазова И.Е., Литвин А.Ю. Артериальная гипертония и синдром обструктивного апноэ во время сна. В кн.: Чазов Е.И., Чазова И.Е. (ред.) Руководство по артериальной гипертонии. М., Media Medica, 2005. С. 182-200.
  54. de Leeuw P.W. Drug-induced hypertension. Recognition and management in older patients. Drugs Aging. 1997;11(3):178-85.
  55. Chapman J.R., Nankivell B.J. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol. Dial. Transplant. 2006;21:2060-63.
  56. Козловская Н.Л., Фомин В.В., Зайцев А.Ю. и др. Ишемическая болезнь почек, развившаяся у больной мезангиокапиллярным гломерулонефритом с нефротическим синдромом // Терапевтический архив. 2005. № 3. С. 79-81.
  57. Фомин В.В., Моисеев С.В., Швецов М.Ю. и др. Ишемическая болезнь почек и сочетанные хронические нефропатии: клинические и прогностические особенности // Терапевтический архив. 2007. № 6. С. 44-49.
  58. Фомин В.В., Моисеев С.В., Лебедева М.В. Феномен сольчувствительности и артериальная гипертония // Врач. 2006. № 3. С. 14-17.
  59. Бобкова И.Н., Чеботарева Н.В., Козловская Л.В. и др. Экскреция с мочой моноцитарного хемотаксического протеина-1 и трансформирующего фактора роста-бета1 как показатель прогрессирования хронического гломерулонефрита // Терапевтический архив. 2006. № 5. С. 9-14.
  60. Dantas M., Romao E.A., Costa R.S., et al. Urinary excretion of monocyte chemoattractant protein-1: a biomarker of active tubulointerstitial damage in patients with glomerulopathies. Kidney Blood Press. Res. 2007;30(5):306-13.
  61. Schwartz N., Su L., Burkly L.C., et al. Urinary TWEAK and the activity of lupus nephritis. J. Autoimmun. 2006;27(4):242-50.
  62. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am. J. Kidney. Dis. 2008;52(3):595-605.
  63. Schmidt-Ott K.M., Mori K., Li J.Y., et al. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007;18:407-13.
  64. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press. Res. 2008;31(4):255-58.
  65. Enghard P., Humrich J.Y., Rudolph B., et al. CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis Rheum. 2009;60(1):199-206.
  66. Yu D., Petermann A., Kunter U., et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J. Am. Soc. Nephrol. 2005;16(6):1733-41.
  67. Petermann A., Floege J. Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. Nephron Clin. Pract. 2007;106(2):c61-c66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies